Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (australia) pty ltd - indapamide hemihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (australia) pty ltd - indapamide hemihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (australia) pty ltd - strontium ranelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (australia) pty ltd - perindopril arginine; amlodipine besylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (australia) pty ltd - agomelatine -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 0.625 mg; perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; maltodextrin; magnesium stearate; colloidal anhydrous silica; macrogol 6000; lactose monohydrate; colour - treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - tipiracil hydrochloride, quantity: 7.065 mg; trifluridine, quantity: 15 mg - tablet, film coated - excipient ingredients: carnauba wax; pregelatinised maize starch; lactose monohydrate; iron oxide yellow; titanium dioxide; macrogol 8000; indigo carmine aluminium lake; hypromellose; stearic acid; iron oxide red; shellac; purified talc; magnesium stearate - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - trifluridine, quantity: 20 mg; tipiracil hydrochloride, quantity: 9.42 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 8000; titanium dioxide; hypromellose; indigo carmine aluminium lake; iron oxide yellow; carnauba wax; magnesium stearate; lactose monohydrate; iron oxide red; shellac; pregelatinised maize starch - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: mannitol; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; hypromellose; carnauba wax; titanium dioxide; macrogol 6000 - latuda is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maltodextrin; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.